ClinicalTrials.gg
CompletedNCT02291510Updated Dec 2, 2016Results posted

Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects

A Phase 1 interventional study of Met DR and Met XR in Healthy Subjects, sponsored by Elcelyx Therapeutics, Inc.. Completed. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-02.

Sponsored by Elcelyx Therapeutics, Inc. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

This study compared the pharmacokinetics (PK) and assessed the safety of delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR, ETB0014) in healthy subjects.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Elcelyx Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 19 to 65 (inclusive) years old at Visit 1 (Screening)
  2. Male, or if female and met all of the following criteria:

    1. Not breastfeeding
    2. Negative pregnancy test result at Visit 1 (Screening) (not applicable to hysterectomized females)
    3. Surgically sterile, , or if of , practiced and was willing to continue to practice appropriate during the entire duration of the study
  3. (BMI) of 25.0 to 35.0 kg/m² (inclusive) at Visit 1 (Screening)
  4. Had a physical examination with no abnormalities as judged by the investigator
  5. Had normal renal function with an estimated (eGFR) ≥90 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation
  6. Ability to understand and willingness to adhere to protocol requirements

Exclusion criteria

Exclusion Criteria:

  1. Had a medical condition as judged by the investigator that could potentially affect study participation and/or personal well-being, including but not limited to the following conditions:

    1. Hepatic disease
    2. Gastrointestinal disease
    3. Endocrine disorder (including diabetes and impaired glucose tolerance)
    4. Cardiovascular disease
    5. Central nervous system diseases
    6. Psychiatric or neurological disorders
    7. Organ transplantation
    8. Chronic or acute infection
    9. Orthostatic hypotension, fainting spells or blackouts
    10. Allergy or
  2. Had any chronic disease requiring medication that was adjusted in the past 90 days (subjects could take acute intermittent over-the-counter medications such as Tylenol, if needed)
  3. Had major surgery of any kind within 6 months of Visit 1 (Screening)
  4. Had a history of >6 kg weight change within 3 months of Visit 1 (Screening)
  5. Had clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormalities judged by the investigator to be clinically significant at Visit 1 (Screening)
  6. Had a physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study
  7. Had any drug treatment that affects gastric pH (prescription or over-the-counter), including any antacids or medications such as Rolaids or Pepcid within 2 days of Visit 1 (Screening)
  8. Currently abused drugs or alcohol or had a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures
  9. Smoked more than 10 cigarettes per day, 3 cigars per day, 3 pipes per day, used more than 1 can of smokeless tobacco per week, or used a combination of tobacco products that approximate nicotine doses equivalent to 10 cigarettes per day
  10. Had donated blood within 3 months of the date of the first dose of randomized study medication, or was planning to donate blood during the study
  11. Had received any drug within 2 months (or five half-lives of the investigational drug, whichever was greater) of the date of the first dose of randomized study medication
  12. Had known allergies or hypersensitivity to any component of study treatment
  13. Was employed by Elcelyx Therapeutics, Inc (that is an employee, temporary contract worker, or designee of the company)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    500 mg Met DR BID

    Two doses of 500 mg metformin delayed-release

    Drug: Met DR

  • Experimental
    1000 mg Met DR BID

    Two doses of 1000 mg metformin delayed-release

    Drug: Met DR

  • Active comparator
    1000 mg Met IR BID

    Two doses of 1000 mg metformin immediate-release

    Drug: Met IR

  • Active comparator
    2000 mg Met XR QD

    Single dose of 2000 mg metformin extended-release

    Drug: Met XR

Interventions

  • DrugMet DR

    metformin delayed-release tablets

  • DrugMet XR

    metformin extended-release tablets

  • DrugMet IR

    metformin immediate-release tablets

06

What researchers measure

Primary outcomes

  1. AUC (0-t) of Plasma Metformin

    AUC (0-t) = Area under the curve from the time of dosing (0 h) to the time of the last quantifiable concentration after the standardized dinner. Doses were administered 1 min prior to 0 h (standardized dinner) for once daily in the evening (qPM) and twice daily (BID) dosing and 1 min prior to 12 h (standardized breakfast) for once daily in the morning (qAM) and BID dosing.

    Time frame: Time points to create AUC (0-t) were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24 hours relative to the start time of the standardized dinner.

  2. Cmax of Plasma Metformin

    Cmax = Maximum concentration from the first dose of study medication administration (0 h) to the time of the last quantifiable concentration following dose administration. Doses were administered 1 min prior to 0 h (standardized dinner) for qPM and BID dosing and 1 min prior to 12 h (standardized breakfast) for qAM and BID dosing.

    Time frame: Time points to create Cmax were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24 hours relative to the start time of the standardized dinner.

07

Results

Posted Sep 21, 2015

Participant flow

Participant flow — Overall Study
MilestoneSequence 1: ABDCSequence 2: BCADSequence 3: CDBASequence 4: DACB
Started5555
Completed treatment a5555
Completed treatment b5554
Completed treatment c5554
Completed treatment d5555
Completed5554
Not completed0001
Withdrew: Adverse event0001

Outcome measures

PrimaryAUC (0-t) of Plasma Metformin

AUC (0-t) = Area under the curve from the time of dosing (0 h) to the time of the last quantifiable concentration after the standardized dinner. Doses were administered 1 min prior to 0 h (standardized dinner) for once daily in the evening (qPM) and twice daily (BID) dosing and 1 min prior to 12 h (standardized breakfast) for once daily in the morning (qAM) and BID dosing.

Time frame:
Time points to create AUC (0-t) were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24 hours relative to the start time of the standardized dinner.
Reported as:
Mean · ng*h/mL
AUC (0-t) of Plasma Metformin
ng*h/mL500 mg Met DR BID1000 mg Met DR BID1000 mg Met IR BID2000 mg Met XR QD
AUC (0-t) of Plasma Metformin6164 ± 4659014 ± 61018709 ± 104416989 ± 968
Statistical analysis
  • 500 mg Met DR BID vs 2000 mg Met XR QD · ANOVA · p = <0.001 · % ratio of ls means: 35.4 · 90% CI 32.27 to 38.74Included treatment, sequence, and period and as fixed effects and subject nested within sequence as a random effect.
  • 1000 mg Met DR BID vs 2000 mg Met XR QD · ANOVA · p = <0.001 · % ratio of ls means: 52.3 · 90% CI 47.77 to 57.36Included treatment, sequence, and period and as fixed effects and subject nested within sequence as a random effect.
  • 500 mg Met DR BID vs 1000 mg Met IR BID · ANOVA · p = <0.001 · % ratio of ls means: 32.1 · 90% CI 29.30 to 35.18Included treatment, sequence, and period and as fixed effects and subject nested within sequence as a random effect.
  • 1000 mg Met DR BID vs 1000 mg Met IR BID · ANOVA · p = <0.001 · % ratio of ls means: 47.5 · 90% CI 43.38 to 52.09Included treatment, sequence, and period and as fixed effects and subject nested within sequence as a random effect.
  • 1000 mg Met IR BID vs 2000 mg Met XR QD · ANOVA · p = 0.0832 · % ratio of ls means: 110.1 · 90% CI 100.50 to 120.68Included treatment, sequence, and period and as fixed effects and subject nested within sequence as a random effect.
PrimaryCmax of Plasma Metformin

Cmax = Maximum concentration from the first dose of study medication administration (0 h) to the time of the last quantifiable concentration following dose administration. Doses were administered 1 min prior to 0 h (standardized dinner) for qPM and BID dosing and 1 min prior to 12 h (standardized breakfast) for qAM and BID dosing.

Time frame:
Time points to create Cmax were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24 hours relative to the start time of the standardized dinner.
Reported as:
Mean · ng/mL
Cmax of Plasma Metformin
ng/mL500 mg Met DR BID1000 mg Met DR BID1000 mg Met IR BID2000 mg Met XR QD
Cmax of Plasma Metformin607 ± 33905 ± 561328 ± 631688 ± 97
Statistical analysis
  • 500 mg Met DR BID vs 2000 mg Met XR QD · ANOVA · p = <0.001 · % ratio of ls means: 35.9 · 90% CI 32.43 to 39.77Included treatment, sequence, and period and as fixed effects and subject nested within sequence as a random effect.
  • 1000 mg Met DR BID vs 2000 mg Met XR QD · ANOVA · p = <0.001 · % ratio of ls means: 53.0 · 90% CI 47.88 to 58.71Included treatment, sequence, and period and as fixed effects and subject nested within sequence as a random effect.
  • 500 mg Met DR BID vs 1000 mg Met IR BID · ANOVA · p = <0.001 · % ratio of ls means: 45.3 · 90% CI 40.88 to 50.13Included treatment, sequence, and period and as fixed effects and subject nested within sequence as a random effect.
  • 1000 mg Met DR BID vs 1000 mg Met IR BID · ANOVA · p = <0.001 · % ratio of ls means: 66.8 · 90% CI 60.34 to 74.00Included treatment, sequence, and period and as fixed effects and subject nested within sequence as a random effect.
  • 1000 mg Met IR BID vs 2000 mg Met XR QD · ANOVA · p = 0.0004 · % ratio of ls means: 79.3 · 90% CI 71.65 to 87.86Included treatment, sequence, and period and as fixed effects and subject nested within sequence as a random effect.

Adverse events

Collected over Approximately 18 to 57 days depending on the number of days between the start of Visit 1 and Visit 2 and the number of washout days between the treatment visits. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
500 mg Met DR BID—0/19 (0%)6/19 (31.6%)
1000 mg Met DR BID—0/19 (0%)3/19 (15.8%)
1000 mg Met IR BID—0/20 (0%)5/20 (25%)
2000 mg Met XR QD—0/20 (0%)10/20 (50%)
Most frequent other events
Showing 10 of 16
Most frequent other events
Event500 mg Met DR BID1000 mg Met DR BID1000 mg Met IR BID2000 mg Met XR QD
HeadacheNervous system disorders2/190/192/202/20
DiarrhoeaGastrointestinal disorders0/191/191/202/20
NauseaGastrointestinal disorders1/190/192/200/20
VomitingGastrointestinal disorders1/191/192/200/20
Catheter Site PainGeneral disorders1/190/191/201/20
AnxietyPsychiatric disorders1/190/190/200/20
InsomniaPsychiatric disorders0/191/190/200/20
Dry ThroatRespiratory, thoracic and mediastinal disorders1/190/190/200/20
Nasal CongestionRespiratory, thoracic and mediastinal disorders1/190/190/200/20
DyspepsiaGastrointestinal disorders0/190/190/201/20

Baseline characteristics

Randomized (ITT) Population

Age, Continuous
Age, Continuous(years)Sequence 1: ABDCSequence 2: BCADSequence 3: CDBASequence 4: DACBTotal
Mean34.2 ± 13.634.8 ± 13.133.8 ± 9.225.8 ± 5.032.2 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1: ABDCSequence 2: BCADSequence 3: CDBASequence 4: DACBTotal
Female10146
Male454114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence 1: ABDCSequence 2: BCADSequence 3: CDBASequence 4: DACBTotal
Hispanic or Latino10023
Not Hispanic or Latino455317
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1: ABDCSequence 2: BCADSequence 3: CDBASequence 4: DACBTotal
American Indian or Alaska Native00112
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American11024
White434213
More than one race01001
Unknown or Not Reported00000
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Sequence 1: ABDCSequence 2: BCADSequence 3: CDBASequence 4: DACBTotal
Mean30.1 ± 4.029.5 ± 2.828.7 ± 2.830.0 ± 1.829.6 ± 2.8
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • DeFronzo RA, Buse JB, Kim T, Skare S, Baron A, Fineman M, editors. Dissociation between Metformin Plasma Exposure and its Glucose-Lowering Effect: A Novel Gut-Mediated Mechanism of Action. 73rd Annual Scientific Meeting of The American Diabetes Association; 2013 June 21-25th; Chicago, Il.
  • Buse JB, DeFronzo RA, Rosenstock J, Kim T, Burns C, Skare S, Baron A, Fineman M. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care. 2016 Feb;39(2):198-205. doi: 10.2337/dc15-0488. Epub 2015 Aug 18. PubMed 26285584 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2014
First posted
Nov 14, 2014
Start
Oct 2012
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results first posted
Sep 21, 2015
Last update
Dec 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02291510
Lead sponsor
Elcelyx Therapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 14, 2014
Start date
Oct 2012
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
Sep 21, 2015
Last update
Dec 2, 2016

Study contacts

Scott Rasmussen, MD
principal investigator · Celerion

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion